At a time when healthcare resources are under pressure, the PGA technology allowing clinicians to select anticancer drugs at highest accuracy which will benefit the patient non-responders is really needed.

Every cancer is unique – different cancers require different treatments, and tumor evolution drives drug resistance, That’s why we need a better theranostics like PGA.

Early prediction of drug response based on pretreatment gene activity portraits (ie., gene expression signature) of cancer has become a necessity.

Scientists at OncoDxRx leveraged gene expression profiles to tackle one of the biggest challenges facing oncology clinicians: drug response prediction for patient non-responders.

OncoDxRx scientists have developed a liquid biopsy-powered gene expression approach, to predict drug response and therapeutic outcome.

Minimal residual disease (MRD) testing, like OncoDxRx's OncoMRD, appears to be a valuable tool for predicting outcomes and potential relapse in patients with cancer.

OncoDxRx’s PGA test provides access – the ability to find a way around. The one-of-a-kind technology can “re-measure the geometry of the tumor with regard to access to more therapeutic options”.

The OncoMRD (OncoDxRx’s molecular residual disease) test can capture and monitor tumor signals longitudinally in a patient's blood to determine how well a treatment is working in less than 5 days.

Facing a variety of cancer threats from different directions, OncoDxRx recently launched a new gene-to-drug assay PGA that can provide rapid drug efficacy results to patients with limited treatment options.

OncoDxRx has invented an exclusive liquid biopsy technology, PGA, for guiding drug discovery, development and repurposing, ultimately to create a more effective and safer therapeutic option for lung cancer patients.

With the promise of saving millions of lives, OncoDxRx's OncoMRD is born